Neonatal community-acquired pneumonia: Pathogens and treatment

被引:9
|
作者
Wang, Hua [1 ]
Tang, Jun [1 ]
Xiong, Ying [1 ]
Li, Xihong [1 ]
Gonzalez, Fernando [2 ]
Mu, Dezhi [1 ,2 ]
机构
[1] Sichuan Univ, W China Univ Hosp 2, Dept Pediat, Chengdu 610041, Peoples R China
[2] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA
关键词
community-acquired pneumonia; drug sensitivity; neonate; pathogen; INFECTIONS; ETIOLOGY; DIAGNOSIS; CHILDREN; AGENTS; RATES;
D O I
10.1111/j.1440-1754.2010.01814.x
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Aim: To analyse the bacterial pathogens and drug sensitivities for neonatal community-acquired pneumonia. Methods: Seven hundred sixty sputum samples from newborns with community-acquired pneumonia were cultured to determine microbial organisms present and their drug sensitivities. Results: Of the 760 specimens, 425 grew pathogens for a 55.9% positive rate. Among the 425 positive cultures, 278 grew gram-negative organisms (65.4%), 142 grew gram-positive organisms (33.3%), while 5 grew fungus (1.3%). The most common gram-negative organisms were Escherichia coli, Klebsiella pneumoniae and Hemophilus influenzae, while the most common gram-positive organisms were Staphylococcus aureus, Staphylococcus epidermidis and Staphylococcus haemolyticus. To the gram-negative organisms, the most sensitive drugs were meropenem, imipenem and amikacin, while to the gram-positive ones were vancomycin, teicoplanin and quinupristin/dalfopristin. Conclusions: The most common causative bacteria were gram-negative organisms, which were highly sensitive to Meropenem, Imipenem and Amikacin, yet often treatable with more focused antibiotic coverage, which depended on the bacterium identified.
引用
收藏
页码:668 / 672
页数:5
相关论文
共 50 条
  • [31] Glucocorticoid treatment in community-acquired pneumonia
    Confalonieri, Marco
    Meduri, G. Umberto
    LANCET, 2011, 377 (9782): : 1982 - 1984
  • [32] Empirical treatment of community-acquired pneumonia
    Ferrer, VF
    Gragera, BA
    Berga, AP
    REVISTA CLINICA ESPANOLA, 2004, 204 (02): : 103 - 105
  • [33] Antimicrobial treatment of community-acquired pneumonia
    Restrepo, MI
    Anzueto, A
    CLINICS IN CHEST MEDICINE, 2005, 26 (01) : 65 - +
  • [34] Treatment failure in community-acquired pneumonia
    Menendez, Rosario
    Torres, Antoni
    CHEST, 2007, 132 (04) : 1348 - 1355
  • [35] CEFOXITIN IN THE TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA
    SALZMAN, C
    POLLY, SM
    SIMON, GL
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1987, 41 (05): : 785 - 789
  • [36] Current treatment of community-acquired pneumonia
    Liapikou, Adamantia
    Torres, Antonio
    EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (10) : 1319 - 1332
  • [37] Community-acquired pneumonia: Diagnosis and treatment
    Sinaniotis, CA
    PEDIATRIC PULMONOLOGY, 1999, : 144 - 145
  • [38] Azithromycin in the treatment of community-acquired pneumonia
    Golec, K
    RzeszutkoGrabowska, M
    BukowskaNierojewska, D
    EXPANDING INDICATIONS FOR THE NEW MACROLIDES, AZALIDES, AND STREPTOGRAMINS, 1997, 21 : 626 - 628
  • [39] Diagnosis and treatment of community-acquired pneumonia
    Lutfiyya, MN
    Henley, E
    Chang, LF
    Reyburn, SW
    AMERICAN FAMILY PHYSICIAN, 2006, 73 (03) : 442 - 450
  • [40] New treatment for community-acquired pneumonia
    不详
    INFECTIONS IN MEDICINE, 2003, 20 (04) : 206 - +